Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of BCMA-CS1 cCAR in Relapsed/Refractory Multiple Myeloma
NCT04156269Phase 1Unknown
- Sponsor
- iCell Gene Therapeutics
- Start
- Aug 2018
- Primary completion
- Sep 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BCMA-CS1 cCAR in multiple myeloma (MM), sponsored by iCell Gene Therapeutics. Primary endpoints: Dose Limiting Toxicity at 28 days, Type of Dose-Limiting Toxicity at 28 days and 1 more. Status: unknown.
02
Drugs
BCMA-CS1 cCAR
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04156269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04156269.